What are the specifications of Relugolix tablets?

Relugolix is a white to off-white to slightly yellow solid with a solubility of 0.04 mg/mL in 25°C water. Repagliflozin is provided in the form of oral film-coated tablets. The European version of the original drug may contain 120mg of Repagliflozin per tablet; the Japanese version of the original drug may contain 40mg of Repagliflozin per tablet.

Regaglic is approved in the United States for the treatment of advanced prostate cancer and in the European Union for the treatment of advanced hormone-sensitive prostate cancer. It can be taken orally (swallowed whole), with or without food. Treatment should be initiated on the first day with a loading dose of 360 mg of Repagliflozin, followed by 120 mg of Repaglifloxacin once daily. Doses should be taken at approximately the same time each day. If treatment is interrupted for more than 7 days, a loading dose of Repagliflozin 360 mg should be resumed, followed by repagofloxacin 120 mg once daily. The most common side effects of Repagliflox (which may affect more than 1 in 5 people) are hot flashes, muscle and joint pain, and fatigue. Other very common side effects are diarrhea and constipation.

The original drug of Regogliflox has not yet been launched in the country, so it is not covered by medical insurance. There are European and Japanese versions of the original drug Rleglik available overseas. The ingredients of the two are basically the same. The price of the European version of 120mg*30 tablets per box may be around RMB 4,000, and the price of the Japanese version of 40mg*100 tablets per box may be around RMB 4,000 (the price may fluctuate due to exchange rates). Currently, there are no generic versions of Repagliflox produced and put on the market.